AR018077A1 - Empleo de derivados de pirrolidina y piperidina, procedimiento para la preparacion de dichos derivados y medicamento que los contiene - Google Patents

Empleo de derivados de pirrolidina y piperidina, procedimiento para la preparacion de dichos derivados y medicamento que los contiene

Info

Publication number
AR018077A1
AR018077A1 ARP990100528A ARP990100528A AR018077A1 AR 018077 A1 AR018077 A1 AR 018077A1 AR P990100528 A ARP990100528 A AR P990100528A AR P990100528 A ARP990100528 A AR P990100528A AR 018077 A1 AR018077 A1 AR 018077A1
Authority
AR
Argentina
Prior art keywords
derivatives
procedure
preparation
pirrolidine
employment
Prior art date
Application number
ARP990100528A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR018077A1 publication Critical patent/AR018077A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Empleo de derivados de pirrolidina y piperidina de las formulas (I) y (II), en donde: R1 y R2 son, independientemente uno de otro, hidrogeno, alcoxiloC1-4, hidroxilo, halogeno, -CONH2 o (C(O)O-alquilo C1-4, o tomados juntos son -O-CH2-O-; R3 y R4 son, independientemente uno de otro, hidrogeno, alcoxiloC1-4, benciloxilo, halogeno, hidroxilo, -CONH2 o -SCH3; o tomados juntos son -O-CH2-O-; R5 es hidrogeno o alquilo C1-4; X e Y son, independientementeuno de otro -CH(OH)-, -(CH2)n-, -C(O)- o -CH(alcoxilo C1-4)-; y m, n y p son 1 o 2; y a sus sales de adicion farmacéuticamente aceptables para lamanufactura de un medicamento util para el tratamiento de enfermedades causadas por sobreactivacion de sub-tipos de receptores de NMDA; procedimientoparala preparacion de dichos derivados y medicamento que los contiene.
ARP990100528A 1998-02-10 1999-02-08 Empleo de derivados de pirrolidina y piperidina, procedimiento para la preparacion de dichos derivados y medicamento que los contiene AR018077A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98102246 1998-02-10

Publications (1)

Publication Number Publication Date
AR018077A1 true AR018077A1 (es) 2001-10-31

Family

ID=8231382

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990100528A AR018077A1 (es) 1998-02-10 1999-02-08 Empleo de derivados de pirrolidina y piperidina, procedimiento para la preparacion de dichos derivados y medicamento que los contiene

Country Status (28)

Country Link
US (2) US6015824A (es)
EP (1) EP0937458B1 (es)
JP (1) JP3142527B2 (es)
KR (1) KR100319249B1 (es)
CN (1) CN1144789C (es)
AR (1) AR018077A1 (es)
AT (1) ATE285766T1 (es)
AU (1) AU748335B2 (es)
BR (1) BR9900742A (es)
CA (1) CA2260698A1 (es)
CZ (1) CZ41099A3 (es)
DE (1) DE69922858T2 (es)
DK (1) DK0937458T3 (es)
ES (1) ES2245808T3 (es)
HR (1) HRP990042A2 (es)
HU (1) HUP9900275A3 (es)
ID (1) ID23456A (es)
IL (2) IL128389A0 (es)
MA (1) MA26607A1 (es)
NO (1) NO990609L (es)
NZ (1) NZ334081A (es)
PE (1) PE20000276A1 (es)
PL (1) PL331336A1 (es)
PT (1) PT937458E (es)
SG (1) SG74120A1 (es)
TR (1) TR199900286A2 (es)
YU (1) YU5899A (es)
ZA (1) ZA991038B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2793245B1 (fr) * 1999-05-05 2002-10-11 Adir Nouveaux composes pyridiniques ou piperidiniques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6369078B1 (en) * 1999-08-31 2002-04-09 J. Phillip Bowen Solenopsin derivatives and analogues as fire ant suppressants
PT1278728E (pt) * 2000-04-20 2004-10-29 Hoffmann La Roche Derivados de pirrolidina e de piperidina e sua utilizacao no tratamento de disturbios neurodegenerativos
JP2004516295A (ja) 2000-12-21 2004-06-03 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー サブタイプ選択的なｎ−メチル−ｄ−アスパラギン酸拮抗薬としてのピペリジン誘導体
MXPA02002749A (es) 2001-03-27 2002-10-28 Warner Lambert Co Derivados de ciclohexilamina como antagonistas del subtipo selectivo del n-metil-d-aspartato.
US7005432B2 (en) * 2002-05-16 2006-02-28 Hoffman-La Roche Inc. Substituted imidazol-pyridazine derivatives
CA2719749A1 (en) * 2008-03-27 2009-10-01 Evotec Neurosciences Gmbh Methods for treating disorders using nmda nr2b-subtype selective antagonist
MX2012002366A (es) * 2009-08-27 2012-03-29 Merck Sharp & Dohme Agonistas novedosos de receptores beta 3 andrenergicos derivados de pirrolidina.
EP2470021B1 (en) * 2009-08-27 2014-10-22 Merck Sharp & Dohme Corp. Novel pyrrolidine derived beta 3 adrenergic receptor agonists

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3941796A (en) * 1970-05-21 1976-03-02 Minnesota Mining And Manufacturing Company α-(Hydroxy and alkoxy substituted)phenyl-α-(2-piperidinyl)-methanols
US4407670A (en) * 1980-02-28 1983-10-04 National Research Development Corporation Biocidal compounds and compositions
US4342692A (en) * 1980-10-20 1982-08-03 Usv Pharmaceutical Corporation Pyrrolidines
ZA825227B (en) * 1981-07-22 1984-03-28 Syntex Inc Substituted pyrrolidine cardiovascular system regulators antihypertensives
IL70753A0 (en) * 1983-01-24 1984-04-30 Syntex Inc +-2-(phenethyl)-5-(3,4-methylenedioxy-alpha-hydroxybenzyl)pyrrolidine and salts thereof,their preparation and pharmaceutical compositions containing them
AU2370084A (en) * 1983-01-24 1984-07-26 Syntex (U.S.A.) Inc. Pyrrolidine derivatives
US4569941A (en) * 1983-03-21 1986-02-11 Usv Pharmaceutical Corp. Method of using phenyl-alkylene-2-pyridyl derivatives to increase cardiac contractility in a mammal
US4548951A (en) * 1983-04-21 1985-10-22 Syntex (U.S.A.) Inc. Hypotensive benzoxathiole pyrrolidines
US4558066A (en) * 1984-05-17 1985-12-10 Syntex (U.S.A.) Inc. Treatment and prevention of ocular hypertension
US4632929A (en) * 1985-01-17 1986-12-30 Usv Pharmaceutical Corp. Method of hypertensive treatment using phenyl-alkylene-2-pyridyl derivatives

Also Published As

Publication number Publication date
HU9900275D0 (en) 1999-04-28
CA2260698A1 (en) 1999-08-10
EP0937458A2 (en) 1999-08-25
IL144456A0 (en) 2002-05-23
MA26607A1 (fr) 2004-12-20
AU1635499A (en) 1999-08-26
HUP9900275A3 (en) 2001-08-28
PL331336A1 (en) 1999-08-16
ES2245808T3 (es) 2006-01-16
PT937458E (pt) 2005-04-29
CN1144789C (zh) 2004-04-07
CZ41099A3 (cs) 1999-09-15
YU5899A (sh) 2001-07-10
TR199900286A3 (tr) 1999-09-21
DK0937458T3 (da) 2005-05-17
PE20000276A1 (es) 2000-04-18
US6015824A (en) 2000-01-18
ATE285766T1 (de) 2005-01-15
DE69922858D1 (de) 2005-02-03
CN1232025A (zh) 1999-10-20
NZ334081A (en) 2000-07-28
NO990609L (no) 1999-08-11
US6153624A (en) 2000-11-28
HUP9900275A2 (hu) 1999-12-28
JP3142527B2 (ja) 2001-03-07
KR19990072459A (ko) 1999-09-27
EP0937458B1 (en) 2004-12-29
IL128389A0 (en) 2000-01-31
EP0937458A3 (en) 2001-05-23
JP2000063384A (ja) 2000-02-29
BR9900742A (pt) 2000-05-09
AU748335B2 (en) 2002-05-30
NO990609D0 (no) 1999-02-09
KR100319249B1 (ko) 2002-01-05
TR199900286A2 (xx) 1999-09-21
SG74120A1 (en) 2000-07-18
DE69922858T2 (de) 2006-04-13
ID23456A (id) 2000-04-27
ZA991038B (en) 1999-08-10
HRP990042A2 (en) 2000-02-29

Similar Documents

Publication Publication Date Title
MX9300786A (es) Compuestos hipolipidaemicos.
ECSP024386A (es) INHIBIDORES DE HMG-Co REDUCTASA Y SU EMPLEO COMO MEDICAMENTO EN EL TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON EL COLESTEROL
UY27092A1 (es) Derivados del novedoso carbamato de quinuclidina y las composiciones medicinales que los contienen
AR032877A1 (es) Inhibidores alquil c(1-6)-4-amino-azepan-3-onicos de proteasas, composiciones farmaceuticas que los comprenden, intermediarios utiles en la preparacion de tales compuestos, procedimiento para la sintesis de dichos inhibidores, y uso de dichos inhibidores en la fabricacion de medicamentos
AR015987A1 (es) DERIVADOS DE PLEUROMUTILINA, COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE, Y, SU USO PARA LA ELABORACIoN DE UN MEDICAMENTO.
AR009052A1 (es) Tienopirimidinas, un procedimiento para su preparacion, empleo de las mismas para preparar un medicamento, preparaciones farmaceuticas que lascontienen y un procedimiento para obtener estas preparaciones farmaceuticas
ES2102195T3 (es) Derivados heterociclicos de acido carbonico que se fijan en receptores de retinoides.
ES2164920T3 (es) Nuevos derivados heterociclicos y uso medicinal de los mismos.
EE9700227A (et) Arüülglütsiinamiidi derivaadid, meetod nende valmistamiseks ja neid ühendeid sisaldavad farmatseutilised preparaadid
ES2169147T3 (es) Derivados de beta-carbolina agonistas de la melatonina, sus procedimientos de preparacion y su utilizacion a titulo de medicamento.
ES2141957T3 (es) Uso de raloxifeno y sus analogos para la produccion de un medicamento para el tratamiento de enfermedades virales.
AR018077A1 (es) Empleo de derivados de pirrolidina y piperidina, procedimiento para la preparacion de dichos derivados y medicamento que los contiene
ES2102144T3 (es) Nuevos derivados de estradieno de 11-benzaldoxima-17beta metoxi-17alfa-metoximetilo un procedimiento para su produccion y productos medicinales que contienen estos compuestos.
ES2159922T3 (es) Nuevos derivados de bencimidazol, de benzoxazol y de benzotiazol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
IT1212896B (it) Metodo di somministrazione per via inalatoria di gangliosidi e derivati, e composizioni farmaceutiche relative
AR002260A1 (es) Compuestos derivados de acido [4-(indazol-3-il)-piperidin-1-il]-acetico, procedimiento para su preparacion, composicion farmacuetica que los contienen,el uso de los mismos en la preparacion de un agente terapeutico, metodo de tratamiento y compuestos intermediarios.
AR004726A1 (es) Derivados 25-hidroxi-16-eno-26,27-bis homo-colecalciferol, compuestos intermediarios para su preparacion, composiciones farmaceuticas que loscontienen y uso de dichos derivados para fabricar un medicamento.
DE69322411D1 (de) Arzneizusammensetzungen enthaltend tandospiron oder seine analoge
ES2125963T3 (es) Nuevos derivados espiranicos del 3-amino-cromano, sus procedimientos de preparacion y las composiciones farmaceuticas que los contienen.
ES2172023T3 (es) Nuevos derivados tetrahidro-piridinicos sustituidos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
AR007369A1 (es) El uso de derivados carboxilados y un medicamento que contiene uno o mas de dichos derivados
BRPI0413101A (pt) compostos de sulfonamida derivado de benzoxazinona, sua preparação e uso como medicamentos
FI950209A (fi) Farmakologisesti aktiiviset alfa-(tertiaarinen-amino-metyyli)-bentseenimetanolijohdannaiset
DK0885004T3 (da) Anvendelse af 4-phenyl-3,6-dihydro-2H-pyridyl-derivater som NMDA-receptor-undertypeblokkere
ES2065192T3 (es) Nuevos nicotinatos de diacil-glicerol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.

Legal Events

Date Code Title Description
FB Suspension of granting procedure